PMID- 27292781
OWN - NLM
STAT- MEDLINE
DCOM- 20170310
LR  - 20220321
IS  - 1875-5607 (Electronic)
IS  - 1389-5575 (Linking)
VI  - 17
IP  - 4
DP  - 2017
TI  - Developments of Anticoagulants and New Agents with Anti-Coagulant Effects in Deep 
      Vein Thrombosis.
PG  - 338-350
AB  - Deep Vein Thrombosis (DVT) has been known as a common medical problem all over 
      the world. Thrombus traveling in blood vessels may lead to pulmonary embolism 
      (PE), associated with high rates of mortality. Anticoagulant therapy is the 
      mainstay treatment of DVT. Common anticoagulants, Vitamin K antagonists (VKAs), 
      unfractionated heparin (UFH) and Low-molecular-weight heparin (LMWH) have been 
      used in clinical application over decades, but can increase the risk of 
      hemorrhage. Thereby, several new oral anticoagulants (NOACs) have been developed, 
      which includes direct thrombin inhibitors (DTI) and direct factor Xa inhibitors. 
      To be contrast with VKAs and UFH, NOACs have many advantages such as rapid offset 
      action, few drug/food interactions and no need for routine coagulation 
      monitoring, etc. Many NOACs are still being evaluated in Phase III clinical 
      trials such as Betrixaban and Darexaban (YM150). However, NOACs still have 
      problems to be solved such as lack of antidotes and laboratory monitoring, high 
      drug costs, etc. Besides, several agents have already shown the potential to be 
      new anticoagulants. Factor Xa play an important role in thrombin generation and 
      coagulation pathway. Thus, the new compounds directly targeting on factor Xa for 
      prevention DVT are highly anticipated. DPC423, a new series of 6-substituted 
      coumarin derivatives and Phenyltriazolinones as potent factor Xa inhibitors have 
      been recently reported. Recent studies revealed that agents extracted from 
      botanicals not only have anti-coagulant effects but also possess other 
      pharmacological activities such as anti-inflammation to alleviate the 
      post-thrombotic syndromes. All the evidence above suggests that many new 
      compounds might have great potential to be more effective and safe oral 
      anticoagulants.
FAU - Dang, Yi-Ping
AU  - Dang YP
FAU - Chen, Yun-Fei
AU  - Chen YF
FAU - Li, Yi-Qing
AU  - Li YQ
FAU - Zhao, Lei
AU  - Zhao L
AD  - Department of Infectious Diseases, Union Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan 430022, China.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Mini Rev Med Chem
JT  - Mini reviews in medicinal chemistry
JID - 101094212
RN  - 0 (Anticoagulants)
RN  - 0 (Coumarins)
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Triazoles)
RN  - A4VZ22K1WT (coumarin)
RN  - EC 3.4.21.6 (Factor Xa)
SB  - IM
MH  - Anticoagulants/administration & dosage/chemistry/*pharmacology/*therapeutic use
MH  - Coumarins/administration & dosage/chemistry/*pharmacology
MH  - Factor Xa/metabolism
MH  - Factor Xa Inhibitors/administration & dosage/chemistry/*pharmacology
MH  - Humans
MH  - Triazoles/administration & dosage/chemistry/*pharmacology
MH  - Venous Thrombosis/*drug therapy
EDAT- 2016/06/14 06:00
MHDA- 2017/03/11 06:00
CRDT- 2016/06/14 06:00
PHST- 2015/01/01 00:00 [received]
PHST- 2016/03/08 00:00 [revised]
PHST- 2016/06/06 00:00 [accepted]
PHST- 2016/06/14 06:00 [pubmed]
PHST- 2017/03/11 06:00 [medline]
PHST- 2016/06/14 06:00 [entrez]
AID - MRMC-EPUB-76424 [pii]
AID - 10.2174/1389557516666160609083649 [doi]
PST - ppublish
SO  - Mini Rev Med Chem. 2017;17(4):338-350. doi: 10.2174/1389557516666160609083649.